0001549595-26-000025
SEC filingQ1 FY2026 delivered sharply lower revenue of $6.3M versus $18.5M prior year due to Sanofi collaboration wind-down, partially offset by Pfizer progress, while escalating R&D personnel costs drove operating loss to -$92.5M from -$62.9M amid pipeline acceleration.
Nurix Therapeutics reported Q1 FY2026 results reflecting collaboration revenue volatility and rising R&D intensity. Revenue fell 66.1% to $6.3 million from $18.5 million in the prior-year quarter. This decline stemmed primarily from the wind-down of the Sanofi collaboration after its initial research term concluded, which reduced recognition under performance obligations. Partially offsetting this was higher revenue from the Pfizer collaboration, driven by a greater percentage of completion of performance obligations in the period, as noted in management's discussion.
Operating expenses escalated, pushing the operating loss to -$92.5 million, a 47.1% worsening from -$62.9 million year-over-year. The operating margin stood at -1479.4%, highlighting the imbalance between revenue contraction and cost growth. Key drivers included increases in compensation and related personnel costs due to headcount expansion across R&D functions. This aligns with the company's strategy to accelerate its pipeline of targeted protein degraders, where development of licensed programs—except those where Nurix elects profit-sharing—is funded at Pfizer's sole cost and expense. These investments underscore Nurix's focus on advancing novel therapies despite near-term profitability pressures.
Looking forward, Nurix expects continued revenue recognition from collaboration upfronts using the cost-based input method. The company may pursue additional capital for strategic opportunities even with sufficient current funds, amid uncertain economic impacts on biotech operations. These dynamics position Nurix to sustain pipeline momentum through disciplined investment.